Van Andel Institute Public Lecture Series: A Focus on Translational Medicine
Have you ever wondered how discoveries made in laboratories become new therapies for diseases like cancer and Parkinson’s?
Join us for the Van Andel Institute Public Lecture Series: A Focus on Translational Medicine on September 25, 2019. Hear from experts in biomedical research and translational medicine, and learn how data from basic research and clinical trials is translated it into new diagnostics and therapies that improve human health.
For more information on what translational research is and why it’s important, please view this informative blog post on VAI Voice.
Registration includes a complimentary boxed lunch and refreshments during the event.
Complimentary valet parking will also be available.
Registration for this event is now closed. Please click here to join our mailing list for information about the Institute and future events.
Stephen Baylin, M.D., studies the body’s genetic control systems—called epigenetics—searching for vulnerabilities in cancer. Baylin is a pioneer in this field and was among the first to trace epigenetic causes of cancer. His studies have led to new therapies for breast, lung and colorectal cancers, among others. He is co-leader of the Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team, a Director’s Scholar at VARI and co-head of Cancer Biology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.
Dr. Steensma received his B.A. from Hope College in Holland, Mich., and his M.D. from Wayne State University School of Medicine in Detroit, Mich. He subsequently completed internship and residency training in the Grand Rapids Orthopaedic Surgery Residency Program. After completing residency, he trained in the laboratories of Drs. George Vande Woude and Rick Hay at VARI under an Orthopaedic Research and Education Foundation training award. Subsequently, Dr. Steensma was admitted into the prestigious fellowship program in Musculoskeletal Surgical Oncology in the Department of Surgery at Memorial Sloan Kettering Cancer Center in New York where he obtained sub-specialty training in the surgical management of musculoskeletal tumors. His fellowship in New York also provided Dr. Steensma with the opportunity to work in the laboratory of Dr. Steve Goldring, Chief Scientific Officer of the Hospital for Special Surgery (HSS) in New York. Dr. Goldring is one of the world’s leading orthopaedic researchers and has a particularly strong reputation for training leading clinician-scientists. During his training with Dr. Goldring, Dr. Steensma further developed his interests in understanding the molecular and cellular mechanisms underlying the development of bone and soft-tissue sarcomas. Dr. Steensma joined Van Andel Research Institute in 2010 as an Associate Scientific Investigator in the Center for Skeletal Disease Research. In 2014, he was named as one of the winners of the inaugural Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research.